Form 4: Olema Pharmaceuticals Director Cyrus Harmon Sells Shares Under 10b5-1 Trading Plan

Director Cyrus Harmon of Olema Pharmaceuticals sold shares of common stock on July 29 and July 30, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Cyrus Harmon, a director at Olema Pharmaceuticals, sold shares of the company's common stock on July 29 and July 30, 2024.
• The sales were executed under a 10b5-1 trading plan adopted on May 16, 2023.
• On July 29, 4,066 shares were sold at a weighted average price of $15.58, with prices ranging from $15.55 to $15.64.
• On July 30, 934 shares were sold at a weighted average price of $15.55, with prices ranging from $15.55 to $15.58.
• Following these transactions, Harmon directly owns 751,283 shares and indirectly owns 122,028 shares through Harmon Family Investors LLC.
• The reporting person is the manager of Harmon Family Investors LLC.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock sales by a company director under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through 10b5-1 trading plans to avoid accusations of insider trading. The disclosure provides transparency into the transactions of company leadership.

Key Dates